Toremifene/Strong CYP3A4 Inducers Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Apalutamide, carbamazepine, dexamethasone, enzalutamide, fosphenytoin, lumacaftor, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentine, and St. John's wort may speed up how quickly your liver processes toremifene. Toremifene may speed up how quickly your body processes phenytoin.
What might happen:
The amount of toremifene in your blood may decrease and it may not work as well. If you are taking phenytoin, the amount of phenytoin in your blood may also decrease and it may not work as well.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together or if you have taken apalutamide, carbamazepine, dexamethasone, enzalutamide, fosphenytoin, lumacaftor, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentine, and St. John's wort in the previous two weeks, or if you stop taking these medicines. Your doctor may want to adjust your medicines. If you are taking phenytoin with toremifene, your doctor may want to check your phenytoin levels.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Fareston (toremifene citrate) US prescribing information. GTx, Inc. March, 2011.
- 2.Anttila M, Laakso S, Nylanden P, Sotaniemi EA. Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther 1995 Jun;57(6):628-35.
- 3.Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998 Dec;64(6):648-54.
- 4.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
- 5.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.